iBio Inc, a biotechnology company, has formally requested the U.S. Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form S-3, initially filed on April 16, 2024. The company seeks to have the registration become effective on April 24, 2024, at 4:00 p.m. Eastern Time. This request was communicated in a letter addressed to Jimmy McNamara at the SEC's Division of Corporation Finance. iBio Inc acknowledges its responsibilities under federal securities laws regarding the issuance of securities covered by the Registration Statement. Leslie Marlow of Blank Rome LLP has been authorized by iBio Inc to modify or withdraw the acceleration request if necessary. The SEC has been asked to notify Ms. Marlow once the acceleration has been granted.

iBio Inc, a biotechnology company, has formally requested the U.S. Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form S-3, initially filed on April 16, 2024. The company seeks to have the registration become effective on April 24, 2024, at 4:00 p.m. Eastern Time. This request was communicated in a letter addressed to Jimmy McNamara at the SEC's Division of Corporation Finance. iBio Inc acknowledges its responsibilities under federal securities laws regarding the issuance of securities covered by the Registration Statement. Leslie Marlow of Blank Rome LLP has been authorized by iBio Inc to modify or withdraw the acceleration request if necessary. The SEC has been asked to notify Ms. Marlow once the acceleration has been granted.